Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants
The International Journal of Neuropsychopharmacology November 4, 2022 Aaron Klaiber, Friederike Holze, Ioanna Istampoulouoglou et al. 100 citations
Abstract Background Lysergic acid diethylamide (LSD) is currently being investigated in psychedelic-assisted therapy. LSD has a long duration of acute action of 8–11 hours. It produces its acute psychedelic effects via stimulation of the serotonin 5-hydroxytryptamine-2A (HT2A) receptor. Administration of the 5-HT2A antagonist ketanserin before LSD almost fully blocks the acute subjective...
DOI: 10.1093/ijnp/pyac075 (opens in new tab)
Full text (opens in new tab)
Lysergic acid diethylamide
Ketanserin
Crossover study
Placebo
+4